Phaseline

Companies › Fidia Farmaceutici

Fidia Farmaceutici: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Paclitaxel (microtubule stabilizer) formulated with hyaluronic acid for intravesical deliv
TubulinPhase 3Bladder Carcinoma in Situ (CIS)May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05024773ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)Phase 3Bladder Carcinoma in Situ (CIS)OncologyMay 2028

Targets

Tubulin (1)

Companies with the same targets

Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen GSK Beijing Biostar Pharmaceuticals Urotronic Ambrx

Companies built like this

Beijing Biostar Pharmaceuticals Verity Pharmaceuticals SecuraBio Sumitomo Pharma Switzerland Eleison Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.